Share Name Share Symbol Market Type Share ISIN Share Description
Horizon Discovery Group Plc LSE:HZD London Ordinary Share GB00BK8FL363 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 94.60 247,648 16:35:20
Bid Price Offer Price High Price Low Price Open Price
94.60 94.80 96.40 90.20 92.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 58.25 -11.51 -3.10 149
Last Trade Time Trade Type Trade Size Trade Price Currency
17:29:45 O 8,310 93.951 GBX

Horizon Discovery (HZD) Latest News

More Horizon Discovery News
Horizon Discovery Takeover Rumours

Horizon Discovery (HZD) Discussions and Chat

Horizon Discovery Forums and Chat

Date Time Title Posts
30/9/202020:01Horizon Discovery Ltd - Genomic translation 1,422
04/10/201812:17Horizon Discovery (HZD) One to Watch -
23/7/201415:43Alan Green says to BUY and HOLD in Horizon-

Add a New Thread

Horizon Discovery (HZD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Horizon Discovery trades in real-time

Horizon Discovery (HZD) Top Chat Posts

Horizon Discovery Daily Update: Horizon Discovery Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker HZD. The last closing price for Horizon Discovery was 94.60p.
Horizon Discovery Group Plc has a 4 week average price of 90p and a 12 week average price of 90p.
The 1 year high share price is 186.80p while the 1 year low share price is currently 90p.
There are currently 157,976,096 shares in issue and the average daily traded volume is 181,212 shares. The market capitalisation of Horizon Discovery Group Plc is £149,445,386.82.
halfpenny: HZD Q3 R&D project driving benefits. HZD Technology driving business customers with UP Front Payments and Royalty. Edit T Cell features changes cell to become a drug. 20/3O million within next 5 years. News update expected this year. Expect return to normality H2. Cash being managed well. EBITDA should improve H2. Staff turnover 15%. IT costs for new website improves services and quality ISO210007 certified this year. Nasdaq listing being worked on. Operating cash flow still positive. Outlook positive and way of working from home working well. Customers relationships improving to a higher level. Outsourcing with sticky services growing H2. Developing screening market and bio production. Drivers remain strong and growing revenue in H2. Q&A Assumption return to growth H2. Driver Academic customers. Customers returning back to work driving demand. RNAI for Covid research online growing. Bio production a challenge and crystal libraries. Outsourcing And Strong Partnership is benefiting HZD. Expecting to outgrow target market overall. Diagnostics and cell line Engineering should grow rapidly and enquiries increasing rapidly. Enjoy HZD price increases for the rest of 2020 and into 2021. My short term Target £1.30 plus plus plus. Future is BRIGHT..
rambutan2: Trading update: Horizon expects to report half year 2020 revenues of approximately GBP22.4 million (HY 2019: GBP26.1 million, c. -13.9%)(1), approximately GBP22.0 million (c. -15.5%) on a constant currency basis. The change was largely due to the rapid reduction of academic research work caused by the COVID-19 pandemic impacting the Group's Research Reagents business unit and was broadly in line with Board expectations. The greatest impact was seen in the second quarter of 2020, most notably in April. This was then followed by a period of sustained recovery, which resulted in large parts of the business regaining momentum and returning towards 2019 levels of revenue by the end of June 2020. Gross margin from continuing operations (1) is expected to be approximately 66.0% (HY 2019: 71.2%). The margin decline is primarily due to the impact of COVID-19 on manufacturing costs and additional provisioning for aged inventory. Adjusted EBITDA is expected to be a loss of GBP4.6 million (HY 2019: GBP0.0 million(1) ). The Group's cash position was bolstered by a successful Placing in April 2020, which raised GBP6.9 million in gross proceeds, and was further strengthened by the implementation of enhanced cash control measures implemented in April. Taking this into account, the Group had cash and cash equivalents of GBP23.6 million as of 30 June 2020 (HY 2019: GBP24.8 million; FY 2019: GBP18.8 million). The Group's strong balance sheet provides financial flexibility to ensure operational delivery and continued strategic investment to fully benefit from market recovery. Terry Pizzie, Chief Executive Officer of Horizon Discovery , commented: "Thanks to the fantastic efforts of our staff, we have continued to operate effectively throughout the crisis and have built stronger and deeper relationships with our biopharma customers based on our ability to add value in difficult conditions. Our customers have increasingly adopted outsourcing as a solution to their own business challenges and we have become recognised as an invaluable long-term partner. "We expect the trend for increased outsourcing to continue, for these relationships to endure and facilitate high level access within our biopharma customer base that will help lay the foundations for commercialising our new high growth areas. "We are encouraged by our H2 2020 prospects and look forward to the remainder of the year with optimism and confidence about the Group's strategy and prospects."
jurgenklopp: Not exactly the most clearly worded RNS !!! If it's recommending efforts to move ahead with the American listing then there is tremendous scope for share price appreciation. If it's recommending efforts be curtailed then please Abcam come and put us out of our misery !!
rambutan2: Wellington took them off Canaccord... htTps://
rambutan2: ...Horizon is already a key supplier for research relating to COVID-19, providing many tools and services to academia and industry to support their efforts in addressing the pandemic. This offering further extends Horizon’s COVID-19 support portfolio: hxxps:// Jesús Zurdo, Global Head Bioprocessing, Horizon Discovery said: “The current coronavirus crisis is highlighting existing shortcomings in the development of much-needed therapeutics. Horizon Discovery is fully committed to help innovators in their efforts to develop new solutions to tackle the COVID-19 pandemic. We are providing immediate access to our state-of-the-art bioproduction platform under very favorable terms to facilitate such efforts.” Terry Pizzie, CEO, Horizon Discovery said: “We are committed to providing flexible, royalty-free access licensing terms and solutions that streamline development and production processes. Building upon more than a decade of experience in cell line engineering, we developed our CHOSOURCE cell line and now support a growing number of pharmaceutical companies in bioproduction. We are doing all that we can to support the fight against COVID-19 and hope that offering rapid access to our CHOSOURCE platform will help to accelerate the development and validation of new therapies to combat the pandemic.”
bouleversee: So that shouldn't reflect on HZD one way or another. Just a tidy up operation between the other 2 companies. I wonder why HZD's share price has shot up today but I haven't checked to see whether the index has also done so. What do you think about their prospects going forward? I'm losing rather a lot on my holding and wondering whether to use the spare cash I have in my ISA to top up, or whether Next, RDSB, SMT, or Photo-Me would be a better bet. or whether none of them is worth topping up. Am losing on all but SMT and the rest of that ISA is a car crash and I wouldn't think of adding. HZD has the (very relevant to me)AIM IHT exemption at present, but for how much longer? And I wonder how long ISAs will survive. The chancellor is going to need to extract as much tax as possible.
jurgenklopp: kestlemill, the simple answer is that Americans value such stocks at far higher values than Brits. With an American listing you can see ValueAct engineering some kind of profitable get out like they did with Merlin Entertainment. Plus you have Cathie Wood from ARKinvest really rating the gene editing sub sector as one of her five categories for growth and, in one of the interviews on youtube, she stated that basically, if people understood how gene editing would affect our futures, the three largest US listed shares in the category would be worth nearer $200 billion rather than the $5 billion they are jointly worth now. Normally one can put these statements down as the rantings of a lunatic. However, over the last couple of years she has become rather well known as the person who said that people were valuing Tesla as a motor manufacturer when it should be treated as a high tech stock and, subsequently, set a price target of $4000 on the share. Therefore her opinions in the last week or so have become rather valued and I suspect many investors will start looking at the other sectors she has championed. ValueAct bought their first hefty chunk of HZD at around 214p where they must have seen some value at the time. They are pretty smart cookies too so you can easily see plenty of momentum behind the share price over the next few weeks or months. As a bonus no more involvement from Woodford cannot do any harm either !!
bouleversee: "Horizon has now exercised its option and Rutgers has granted it an exclusive license to Rutgers' proprietary Base Editing technology. The license includes the right for Horizon to sublicense the technology to entities seeking to use it for therapeutic development. Financial terms are confidential and have not been disclosed." Despite Terry Pizzie's statement that this should be transformative for HZD as it is claimed to be better/safer than Crispr/cas9 (see notes to Editors), the share price has dropped a fair bit rather than risen, as I had expected, however.
kestelmill: I've heard Centauri therapeutics is closing down, with the implication that Avvinity will be going on ice. I'm not sure if this would have a positive or negative impact on the share price. I would have thought positive but then it has lost 9% today? Any thoughts?
jurgenklopp: Yes indeed bouleversee. Woodford has been selling his most liquid stocks over the last day or two and the HZD price is getting clobbered just in anticipation of his holding being offered soon. For a day trader I would suggest there is little scope to get the timing exactly right as to where the turning point will be. However I take the view that firstly ValueAct considered HZD worth an initial large investment at 214p (if I recall correctly), secondly we are at the levels where Abcam tried a bid offering a premium (pitched at 180p) a couple of years ago, and thirdly, for any would be bidder (Abcam, Softbank or anyone else) we have a desperate seller holding 12% of the Company - a superb base from which to plan a takeover. I am not going to get the timing exactly right but these are currently outstanding value in my opinion.
Horizon Discovery share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Horizon Di..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201001 22:55:10